<DOC>
	<DOCNO>NCT00897949</DOCNO>
	<brief_summary>A study evaluate rizatriptan/MK0462 ( 5 10 mg ) treatment acute migraine attack treatment two headache recurrence compare placebo . The long term extension study pool patient MK0462-022 , -025 , -029 describe NCT01286207 .</brief_summary>
	<brief_title>MK0462 Treatment Migraine With Recurrence ( MK0462-022 )</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Patient least 6month history migraine , without aura Patient male , female must postmenopausal , surgically sterilize , take adequate contraceptive precaution Patient judge good health , apart migraine Patient pregnant nursing mother Patient abuse drug alcohol within 12 month prior enter study Patient history cardiovascular disease Patient clinically significant ECG abnormality Patient rest systolic blood pressure great 145 mm Hg diastolic le 95 mm Hg screening Patient receive treatment investigational device compound within 30 day study start Patient typically suffer less 1 8 attack migraine per month Patient difficulty distinguish his/her migraine attack tension interval headache Patient prior exposure rizatriptan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>